News for BiomX Inc. (PHGE-WT)

BiomX (PHGE) CEO Jonathan Solomon to present at Biomed Israel 2025 Conference on May 21, 2025. Focus on positive topline Phase 2 results for BX211, a ph

**media[630522]**

Analyst Joseph Pantginis from H.C. Wainwright has adjusted the price target for BiomX (PHGE), reducing it from $21 to $15. The adjustment follows the company's

Cash Balance and Restricted Cash: $21.2 million as of March 30, 2025, compared to $18 million as of December 31, 2024.Research and Development Expenses: $5.3 m

May 15, 2025 / 06:00PM GMTOperator Greetings and welcome to the BiomX Inc first quarter 2025 financial results conference call. At this time, all participants a

BiomX Inc. (NYSE:PHGE) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ETCompany ParticipantsMarina Wolfson - CFOJonathan Solomon - CEOConference Call...

BiomX (PHGE) reports positive Phase 2 trial results for BX211 in treating diabetic foot osteomyelitis, with statistically significant improvements in ulcer

**media[626768]**

BiomX Inc. (PHGE), a clinical-stage company focused on phage therapies that target specific pathogenic bacteria, announced Monday positive, topline safety and efficacy results from its Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis or DFO.

**media[581154]**

Net Loss: $17.7 million for 2024, a significant improvement from the $26.2 million loss in the previous year.Cash Position: Ended 2024 with $18.0 million in ca

**media[575685]**

**media[571268]**

BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsMarina Wolfson – Chief Financial OfficerJonathan...

The following slide deck was published by BiomX Inc.

**media[465882]**

**media[463917]**

Biomx stock plunges to 52-week low, hits $0.87

**media[436916]**